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Introduction
Treating tuberculosis (TB) disease benefits not only the individual patient but the community as a whole. 
Thus, any health care provider undertaking treatment of a patient with TB, whether a public health or 
private practitioner, is assuming a public health function that includes the responsibility for not only 
prescribing an appropriate regimen but also ensuring the patient’s adherence to the regimen until 
treatment is completed.
Recommended Regimens
There are 10 drugs currently approved by the U.S. Food and Drug Administration (FDA) for treating 
TB. Of the approved drugs, the first-line anti-TB agents that form the core of treatment regimens are
• isoniazid (INH),
• rifampin (RIF),
• ethambutol (EMB), and
• pyrazinamide (PZA).
Regimens for treating TB disease have an intensive phase of 2 months, followed by a continuation phase of 
either 4 or 7 months. The continuation phase should be extended to 28 weeks for patients who have 
cavitation on the initial chest film and positive sputum cultures after 2 months of treatment. Treatment 
completion is determined by the number of doses ingested over a given period of time. Although basic TB 
regimens are broadly applicable, there are modifications that should be made under special circumstances 
(i.e., HIV infection, drug resistance, pregnancy, or treatment of children). Listed below are the basic 
regimens; please refer to Treatment of TB1 for all options for the treatment of drug-susceptible TB.
Basic TB Treatment Regimens
Preferred Regimen Alternative Regimen Alternative Regimen
Intensive Phase 
Daily INH, RIF, PZA, and 
EMB* for 40-56 doses** (8 
weeks)
Intensive Phase  
Daily INH, RIF, PZA, and EMB* for 14 
doses (2 weeks), then three-times-
weekly for 18 doses (6 weeks)
Intensive Phase  
Three-times-weekly INH, RIF, 
PZA, and EMB* for 24 doses (8 
weeks)
Continuation Phase  
Daily INH and RIF for 90-126 
doses** (18 weeks) or three-times 
weekly INH and RIF for 54 doses 
(18 weeks)
Continuation Phase  
Three-times-weekly INH and 
RIF for 54 doses (18 weeks)
Continuation Phase 
Three-times-weekly INH and 
RIF for 54 doses (18 weeks)
* EMB can be discontinued if drug susceptibility studies demonstrate susceptibility to first-line drugs.
** Guidelines allow dosing 5 or 7 days-a-week; 5 days-a-week administration by DOT is an acceptable alternative to 7 days- 
      a-week administration.
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A continuation phase of once-weekly INH and rifapentine can be used for HIV-negative patients who 
do not have cavities on the chest film and who have negative acid-fast bacilli (AFB) smears at the 
completion of the intensive phase of treatment.
Case Management
Patient-centered case management should be used in the treatment strategy with an adherence 
plan that includes directly observed therapy (DOT). DOT is a strategy in which a health care worker or 
another designated person watches the TB patient swallow each dose of the anti-TB drugs. All patients 
taking drugs fewer than 7 days per week (e.g., 1, 2, 3, or 5 days a week) must receive DOT.  
Follow-up Evaluations
Sputum specimens for microscopic examination and culture should be obtained from patients 
diagnosed with TB disease at a minimum of monthly intervals until two consecutive specimens are 
negative on culture. It is critical to obtain a sputum specimen at the end of the intensive phase (2 
months) to determine if the continuation phase should be extended. In addition, it is essential that 
patients have clinical evaluations at least monthly to identify possible adverse effects of the anti-TB 
medications and to assess adherence. All patients with TB disease should have counseling and testing 
for HIV.
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